A multi-center, prospective observational study to evaluate the effectiveness of a single-pill combination of amlodipine, losartan, rosuvastatin, and ezetimibe in patients with hypertension and dyslipidemia

Pusan National University Yangsan Hospital0 个研究点目标入组 550 人开始时间: 待定最近更新: 2023年8月1日

试验速览

暂无简介。

•1.Patient diagnosed with essential hypertension and primary hypercholesterolemia, scheduled for treatment with a combination medication containing amlodipine, losartan, rosuvastatin, and ezetimibe.
•2.Patient diagnosed with essential hypertension or primary hypercholesterolemia, currently receiving treatment with antihypertensive or lipid-lowering medications, planning to switch to a combination medication containing amlodipine, losartan, rosuvastatin, and ezetimibe.

•1.According to the approval indications, the combination medication containing losartan and amlodipine should not be administered in cases where there are contraindications specified.
•2.The statin class medications (such as rosuvastatin, atorvastatin) and ezetimibe should not be administered in cases where there are contraindications specified.
•3.Patients with suspected secondary hyperlipidemia or secondary hyperlipidemia, such as nephrotic syndrome, proteinuria, obstructive liver disease, Cushing's syndrome, etc.
•4.If the patient has received investigational drugs for clinical trials within 4 weeks prior to the registration date, or plans to participate in other clinical trials during the study period.

发起方